Back to Peptides
Fat LossMedium Risk

CJC-1295

Also known as: CJC-1295 DAC, Drug Affinity Complex GHRH

Half-life:
6–8 days (DAC form)

Administration Routes

subcutaneous
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

CJC-1295 binds to and activates pituitary GHRH receptors, stimulating pulsatile GH secretion. The DAC modification enables covalent binding to albumin, dramatically extending the active peptide half-life. This sustained GH pulse pattern is intended to mimic physiological GH release more closely than shorter-acting GHRH analogues.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) form binds to albumin in the bloodstream, extending its half-life to several days and enabling sustained elevation of GH and IGF-1 levels. It is commonly researched alongside GHRP peptides for body composition and recovery outcomes.

Primary Research Areas

  • fat_loss
  • recovery
  • performance

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Providers Offering CJC-1295